Adverse events affecting recovery from seasonal influenza 1

vaccination in the hypertensive population: A population-based 2

pharmacovigilance analysis 3

- Short title: AEs affecting flu vaccine recovery in hypertensives 4
- Hao Wu^{1,2}, Xiaona He^{1,2}, Yu Cao^{1,2}, Wei Gao^{1,2,*} 5
- 6
- 7 ¹ Department of Epidemiology & Health Statistics, School of Public Health, Jiangxi
- 8 Medical College, Nanchang University, Nanchang, Jiangxi, China
- ² Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, 9
- 10 Nanchang University, Nanchang, China
- 11
- *Corresponding author 12
- 13 E-mail: wei.gao@ncu.edu.cn (Wei Gao)
- 14

Abstract 15

Seasonal influenza vaccination is crucial for preventing influenza and its complications. 16

- Data from the U.S. Vaccine Adverse Event Reporting System (VAERS) indicate a 17
- higher proportion of adverse events (AEs) after influenza vaccination in hypertensive 18
- people. However, there is limited evidence on AEs in hypertensive people following 19
- seasonal influenza vaccination. We collected a total of 4647 individuals on seasonal 20
- 21 influenza vaccination and 6380 AEs from VAERS for hypertensive people aged 18

22	years or older from 1 January 2013 to 23 June 2023. We conducted propensity score
23	matching (PSM) by adjusting for the demographic characteristics of the seasonal
24	influenza-vaccinated hypertensive population and the season of onset. Cox regression
25	analysis was used to calculate the risk ratio of reported adverse events (AEs) that
26	affected recovery after seasonal influenza vaccination. Most AEs were nonserious and
27	occurred within 48 hours. The most common AEs were general disorders and
28	administration site conditions (therapeutic and non-therapeutic responses,
29	inflammation) and musculoskeletal and connective tissue disorders (musculoskeletal
30	and connective tissue pain and discomfort, bursal disorders, joint-related signs, and
31	symptoms). All three types of seasonal influenza vaccines were associated with
32	injection site reactions (47.07% trivalent influenza vaccine [TIA], hazard ratio, HR
33	2.04, 95% confidence interval, CI1.22–3.40; 20.00% quadrivalent influenza vaccine
34	[QIA], HR 2.81, 95% CI, 1.81–4.37; 67.48% influenza vaccine, unknown manufacturer
35	[FLUX], HR 2.83, 95% CI, 1.12–7.15) and were the AEs affecting the largest
36	proportion of delayed recoveries in the hypertensive population. Potential AEs
37	following seasonal influenza vaccination may affect the recovery of the hypertensive
38	population. The majority of AEs reported were general disorders, predominantly
39	injection site reactions, and nonserious.

40

41 Introduction

42 Influenza is a highly transmissible viral infection caused by the influenza virus, leading

43	to severe respiratory illnesses in approximately 3-5 million people and 290,000-
44	650,000 deaths globally every year[1,2]. Influenza has become a serious public health
45	issue. Since the 20th century, several influenza pandemics have occurred in human
46	history, such as the 'Spanish Flu' in 1918–1919, the 'Asian Flu' in 1957–1958, the
47	'Hong Kong Flu' in 1968–1969, the 'Swine Flu' in 1976, the 'Russian Flu' in 1977,
48	and the Influenza A in 2009, which also caused millions of deaths[3,4]. Pandemic and
49	seasonal influenza cause substantial morbidity and mortality worldwide, posing a
50	serious threat to public health and the global economy[5]. Seasonal influenza infections
51	occur in all age groups, but children under 59 months of age, adults over 65 years of
52	age, and pregnant women are more vulnerable[6-8]. Despite the high incidence of
53	annual seasonal influenza infections, annual vaccination programs remain a critical
54	public health tool to reduce the disease burden of seasonal influenza[9]. Currently,
55	seasonal influenza vaccines are produced as 'trivalent' or 'quadrivalent'
56	formulations[10,11]. Seasonal influenza vaccines are generally considered safe;
57	however, they can sometimes cause adverse events following immunization (AEFIs).
58	Generally, AEFI is deemed less serious than influenza[12]. Therefore,
59	pharmacovigilance (PV) is an important tool for monitoring AEFI and confirming the
60	benefits of immunization in different target groups[13].
61	The U.S. Vaccine Adverse Event Reporting System (VAERS) was created in
62	1990 and co-administered by the U.S. Centers for Disease Control and Prevention
63	(CDC) and the U.S. Food and Drug Administration (FDA) to collect spontaneous

64	reports of adverse events (AEs) and manage vaccine safety VAERS accepts reports of
65	AEs from health-care providers, vaccine manufacturers, and the public[14,15]. The
66	main objectives of VAERS are to detect new, unusual, or rare vaccine AEs; assess the
67	safety of newly approved vaccines; make new recommendations for existing vaccines;
68	identify potential risk factors, monitor the increase in known AEs; and determine and
69	address possible reporting clusters[16]. Real-world monitoring of vaccine safety is
70	crucial for understanding suspected AEFIs, assessing their incidence, and determining
71	risk factors to identify potential vaccine contraindications[17]. Moreover, the recently
72	published World Health Organization (WHO) guidelines on the economic evaluation of
73	influenza vaccination suggest considering AEFI when possible[18]. Error! Reference source not
74	found.
75	Although influenza is mostly self-limiting, serious complications can occur in
76	vulnerable patient groups[12]. Hypertension is an established cardiovascular risk factor
77	for the general population. Patients with hypertension are regarded as a high-risk group
78	for being infected with seasonal influenza due to the high possibility of a compromised
79	immune system, especially in the elderly[19,20]. The WHO[1] and U.S. CDC[21]
80	recommend that patients with chronic diseases should be priority groups for influenza
81	vaccination. The Chinese CDC has recommended that it is of vital importance for older
82	hypertensive patients to receive an influenza vaccine[22], which is consistent with the

- recommendations of the U.S. CDC[23]and the WHO. One study showed that the
- 84 coverage rate of influenza vaccinations in which only 0.4% of people with chronic

85	diseases had received an influenza vaccine[24], a history of influenza vaccination, and
86	the perceived safety and effectiveness of the vaccination are responsible for the lower
87	values of influenza vaccination coverage in mainland China[25,26].
88	Thus, the objective of our study was to better understand the AEs affecting
89	recovery from seasonal influenza vaccination in the hypertensive population. We
90	investigated all possible AEs for the three types of seasonal influenza vaccines
91	(trivalent influenza vaccine [TIA], quadrivalent influenza vaccine [QIA], and influenza
92	vaccine, unknown manufacturer [FLUX]) between January 1, 2013, and June 23, 2023
93	on the VAERS database.

94

95 Materials and Methods

96 Study data selection

A total of 81,713 AEs were initially investigated during the study period; of these, 4647
individuals with a history of hypertension with a unique VAERS ID were screened:
2135 for TIA, 2300 for QIA, and 212 for FLUX. The primary endpoint was all AEs
within one month in individuals with a history of hypertension. The exclusion criteria
were missing data on age or being under 18 years of age, missing data on the number of
days associated with vaccine-related AEs, cases reported after one month, failure to
report recovery from vaccine-induced AEs, outliers or flawed logic, and data for which

- 104 the year of vaccination did not coincide with the year reported. S1 Fig displays the
- 105 workflow, illustrating the data collection process and the number of individuals

106 excluded at different stages.

107

Study population 108 Data from the original reports are publicly available as an online downloadable dataset 109 on the VAERS website, with sensitive patient information removed[14]. The raw 110 dataset comprised three distinct files in the VAERS database between January 1, 2013, 111 112 and June 23, 2023. It included demographic information and medical history in VAERSDATA, vaccination-associated adverse symptoms in VAERSSYMPTOMS, 113 and vaccine type in VAERSVAX. We identified all cases related to the seasonal 114 influenza vaccine by using a unique case identification number in the raw dataset. We 115 examined the medical records for each individual's medical history, particularly 116 focusing on pre-diagnosed diseases at the time of seasonal vaccination. We used 117 keywords such as high blood pressure, hypertension, HBP, and high blood pressure to 118 extract individuals with a history of high blood pressure as the primary population. The 119 analysis of medical records included general information (VAERS ID, age, sex, state, 120 and medical history when vaccinated), vaccination information (vaccine type, 121 vaccination date, AEs onset date, and the interval between the vaccination date and the 122 occurrence of AEs), and recovery from vaccine-induced AEs. 123 124

125 Selection of AE reports

126 According to the unique ID identification number, 4647 individuals with a history of

127	hypertension were included after the deletion of blank values, age under 18 years, and
128	certain records with logical errors. Additionally, we examined five adverse symptoms
129	for each participant to more precisely measure the AEs affecting their recovery from
130	seasonal influenza vaccination. Seasonal influenza vaccine AEs were defined as reports
131	submitted that contained the word 'FLU', but did not specifically mention H1N1
132	influenza in the vaccine code. To compare the different types of seasonal influenza
133	vaccines, we classified them into three primary categories: (1) TIA, including FLU3,
134	FLUA3, FLUC3, FLUR3, and FLUN3; (2) QIA, including FLU4, FLUA4, FLUC4,
135	FLUR4, and FLUN4; and (3) FLUX with no brand name.
136	

137 Standard medical terms for vaccine AEs

The Medical Dictionary for Regulatory Activities (MedDRA) is a medical coding 138 139 dictionary used by regulatory authorities, pharmaceutical companies, clinical research organizations, and health care professionals[27]. MedDRA is organized into a 140 five-level hierarchy, with the highest level being the Systematic Organ Classification 141 (SOC), which is further divided into High-Level Group Terms (HLGT), High-Level 142 Terms (HLT), Preferred Terms (PT), and Low-Level Terms (LLT). In release version 143 26.1[28], the hierarchy consists of 27,337, 1738, 24,313, and 81,885 terms. The 144 VAERS database provides several AEs at the PT level, but these are highly fragmented 145 into signs, symptoms, diagnoses, investigations, or medical procedures, which may fail 146 to recognize differences in the incidence of AEs[29]. Therefore, we converted the 147

standard terminology associated with all AEs (PT) into HLT[30]. AEs at the primary

149 SOC level were selected for MedDRA's hierarchical structure analysis.

150 Statistical analysis

151 The VAERS database collected data on age groups, sex, region, and season of onset.

152 The type of vaccine used may depend on individual characteristics; therefore,

153 individual choices may influence vaccine-associated AEs and recovery. Therefore, we

applied propensity score matching (PSM) to reduce bias due to these confounding

variables. A nearest-neighbor approach with a 1:1 matching ratio was used. PSM shifts

the regulation of confounders to the control of propensity scores to 'downscale' and to

157 control for confounding bias. The propensity score (PS) for seasonal influenza vaccine

exposure was estimated using logistic regression modeling with age group (18-59,

159 60-64, 65-69, 70-74, 75-79, and \geq 80 years), region (West, Midwest, Northeast, South,

160 and Overseas territory), sex (female and male), and season of onset (spring including

161 March, April, and May; summer including June, July, and August; fall including

162 September, October, and November; and winter including December, January, and

163 February) as predictors. To control for confounding variables, estimates were obtained

using a binomial logistic regression analysis. The caliper value was defined as

165 '0.2×standard deviation of the PS estimates with logit transformation applied'.

166 Standardized mean difference (SMD) was calculated to assess variable balance in the

167 matched data, and a SMD value <0.1 was considered balanced[31]. Using PS estimates

and caliper values, the hypertensive population seasonal influenza vaccine recovery and

non-recovery groups were matched. The case selection for proportional imbalanceanalysis is shown in S1 Fig.

171	A total of 6380 seasonal influenza vaccine-induced AEs reported for each
172	individual over one month were considered independent variables in our study. The
173	dependent variable was whether the hypertensive population recovered from influenza
174	vaccine-induced AEs or not. Cox proportional hazards regression analysis was used to
175	examine the association between these AEs and recovery. AEs with a total frequency of
176	less than 10 were removed to address any monotonic likelihood issues that may have
177	occurred in the Cox proportional hazards regression models[30]. The results of the Cox
178	regression models are expressed as hazard ratios (HR) and 95% confidence intervals
179	(CI). A consistency index was used to determine the discriminatory power of the
180	multivariate Cox proportional hazard regression model. All statistical analyses were
181	performed using R version 4.3.2 (R Foundation for Statistical Computing, Vienna,
182	Austria). Prism version 9 (GraphPad Software, USA) was used as a mapping tool, and
183	the MedDRA desktop viewer was used for hierarchical structure analysis of the medical
184	terms[29,30].

185

186 **Results**

187 Of the 4647 validated cases with a history of hypertension, the mean baseline age of the

- study participants was 64.46 years. The gender distribution was 3132 females
- 189 (67.40%), and 1500 males (32.28%), with a male-to-female ratio of approximately

190	1:2.08. The southern region had the highest number of seasonally influenza-vaccinated
191	hypertensive individuals (34.02%). In contrast, there was little difference in the number
192	of individuals vaccinated in the western (22.04%) and midwestern regions (23.28%).
193	The AE period coincided with the peak season for seasonal influenza vaccination in
194	autumn, which had the highest number of episodes among the four seasons.
195	Additionally, the AEs episode interval for the seasonal influenza vaccine was 3.30
196	days: 3.03 for TIA; 3.38 for QIA; and 5.06 for FLUX. The results showed that 2188
197	(47.08%) patients in the hypertensive population did not recover from AEs (Table 1).
198	After PSM was paired at 1:1 ratio to eliminate selection bias, the caliper width was
199	adjusted to 0.2, resulting in the disappearance of differences between groups
200	(SMD<0.1, P>0.05). The total number of seasonal influenza vaccinations after
201	matching was 3914. We found differences in age, sex, region, and season of onset
202	between the non-recovered and recovered groups in the hypertensive population before
203	PSM for TIA, QIA, and FLUX (S1-S3 Tables).

204

205 Table 1. Demographic characteristics of seasonal influenza vaccination in the

V(%)] QIA [$N(%)$	FLUX [N(%)]	Total $[N(\%)]$
45.95) 2300(49.49)) 212(4.56)	4647(100.00)
±11.51 61.35±13.09	9 59.28±13.86	64.46±12.94
7.70) 938(40.78)	102(48.11)	1418(30.51)
.42) 395(17.17)	26(12.26)	558(12.01)
8.81) 379(16.48)	34(16.04)	1028(22.12)
8.78) 241(10.49)	24(11.32)	666(14.13)
3.54) 185(8.04)	11(5.19)	485(10.44)
	$(X(76)]$ $QIA[X(76)]$ $45.95)$ $2300(49.49)$ ± 11.51 61.35 ± 13.09 $7.70)$ $938(40.78)$ $.42)$ $395(17.17)$ $8.81)$ $379(16.48)$ $8.78)$ $241(10.49)$ $3.54)$ $185(8.04)$	$(N(78))$ $(QIA [N(78)]$ $PLOA [N(78)]$ 45.95) $2300(49.49)$ $212(4.56)$ ± 11.51 61.35 ± 13.09 59.28 ± 13.86 7.70) $938(40.78)$ $102(48.11)$.42) $395(17.17)$ $26(12.26)$ 8.81) $379(16.48)$ $34(16.04)$ 8.78) $241(10.49)$ $24(11.32)$ 3.54) $185(8.04)$ $11(5.19)$

206 hypertensive population.

	≥80	315(14.75)	162(7.04)	15(7.08)	492(10.59)
	Female	1447(67.78)	1548(67.30)	137(64.62)	3132(67.40)
Sex	Male	679(31.80)	746(32.44)	75(35.38)	1500(32.28)
	Unknown	9(0.42)	6(0.26)	0(0.00)	15(0.32)
	West	495(23.19)	469(20.39)	60(28.30)	1024(22.04)
	Midwest	460(21.55)	576(25.04)	46(21.70)	1082(23.28)
State	Northeast	434(20.33)	399(17.35)	37(17.45)	870(18.72)
	South	712(33.35)	807(35.09)	62(29.25)	1581(34.02)
	Overseas territory	34(1.58)	49(2.13)	7(3.30)	90(1.94)
	Spring	224(10.49)	250(10.87)	14(6.60)	488(10.50)
Ongot googon	Summer	308(14.43)	303(13.17)	28(13.21)	639(13.75)
Oliset season	Autumn	1271(59.53)	1375(59.79)	137(64.62)	2783(59.89)
	Winter	332(15.55)	372(16.17)	33(15.57)	737(15.86)
Daaayaru	Yes	1263(59.16)	1096(47.65)	100(47.17)	2459(52.92)
Recovery	No	872(40.84)	1204(52.35)	112(52.83)	2188(47.08)
AEs onset interval(day	s) [mean (SD)]	3.03 ± 27.46	3.38 ± 21.90	5.06±27.52	3.30 ± 24.86
AEs median onset inter	rval(range) in days	0(0–1097)	0(0-731)	1(0-359)	0(0-1097)

207 SD, standard deviation; TIA, trivalent influenza vaccine; QIA, quadrivalent influenza vaccine;

FLUX, influenza vaccine, unknown manufacturer; AEs, adverse events. 208

209

210	In the PS-matched	hypertensive	population.	, 75 AEs with	TIA have been re	ported
-----	-------------------	--------------	-------------	---------------	------------------	--------

in the PS-matched hypertensive population. Furthermore, we identified 12 AEs 211

affecting recovery that were associated with the estimated risk of occurrence using a 212

multivariate Cox regression model with a consistency index of 0.58. Overall, 12 AEs 213

were linked to TIA (Fig 1), with an adjusted HR range of 1.82 to 3.91, and were 214

categorized into eight SOC terms (S4 Table). Among the SOC terms, two common AEs 215

accounted for the majority: general disorders and administration site conditions 216

(61.68%) and musculoskeletal and connective tissue disorders (23.85%). Especially, 217

injection site reactions (47.07%; HR=2.04; 95% CI, 1.22-3.40), musculoskeletal and 218

219 connective tissue pain and discomfort (15.71%; HR=2.40; 95% CI, 1.43-4.10), pain

220	and discomfort NEC (13.11%; HR=1.99; 95% CI, 1.17–3.40) showed an increased risk
221	of non-recovery in hypertensive individuals. After the QIA, 94 AEs were reported, and
222	57 AEs were estimated using the multivariate Cox regression model, with a consistency
223	index of 0.63 (Fig 2). The adjusted HR distribution ranged from 2.08 to 5.85 and was
224	grouped into 15 SOC terms (S5 Table).
225	



241	disorders	(14.95%), skin and	l subcutaneous tissue	e disorders	(12.17%), and nervous
-----	-----------	--------------------	-----------------------	-------------	-----------------------

- system disorders (9.63%). Among them, injection site reactions (20.00%; HR=2.81;
- 243 95% CI, 1.81–4.37), musculoskeletal and connective tissue pain and discomfort
- 244 (6.84%; HR=3.69; 95% CI, 2.35–5.78), pain and discomfort NEC (6.34%; HR=3.67;
- 245 95% CI, 2.33–5.78), asthenic conditions (5.39%; HR=2.25; 95% CI, 1.41–3.58)
- typically exhibited a higher risk with QIA. Additionally, 28 AEs with FLUX were
- observed and five AEs were associated with the risk of developing AE, as estimated by
- the multivariate Cox regression model (Fig 3). The consistency index is 0.59. The
- adjusted HR distribution ranged from 2.83 to 6.31 and was subsequently categorized
- 250 into three SOC terms (S6 Table). General disorders, administration site conditions
- 251 (71.54%), and musculoskeletal and connective tissue disorders (23.58%) were the most
- 252 frequent (similar to the TIA results). In particular, injection site reactions (67.48%;
- 253 HR=2.83; 95% CI, 1.12–7.15), tissue condition NEC (13.01%; HR=3.64; 95% CI,
- 254 1.29–10.23), and joint-related signs and symptoms (10.57%; HR=3.75; 95% CI, 1.25–
- 11.26) were at heightened risk in the non-recovery group. A comparison of PSM before
- and after TIA, QIA, and FLUX vaccinations is shown in S2 Fig.
- 257

258 Fig 3. Adverse events (AEs) hazard ratios after influenza unknown manufacturer

259 (FLUX) vaccination estimated from a multivariate Cox proportional hazard

- 260 **model.** The results showed five influenza unknown manufacturer (FLUX)
- vaccine-induced adverse events (AEs) with a statistically significant difference

(*P*<0.05), estimated using multivariate Cox proportional hazard regression analysis. N
denotes the number of adverse cases in the non-recovered group; HR, hazard ratio; CI,
confidence interval.

265

266 **Discussion**

We analyzed whether major AEs influenced recovery following seasonal influenza 267 vaccination in a hypertensive population. Among the 27 SOCs examined, four terms 268 (general disorders and administration site conditions, musculoskeletal and connective 269 tissue disorders, skin and subcutaneous tissue disorders, and nervous system disorders) 270 were associated with a higher frequency of AEs in the PS-matched hypertensive 271 population. Among the non-recovery group, the most common AEs were injection site 272 reactions, musculoskeletal and connective tissue pain and discomfort, pain and 273 discomfort NEC, and joint-related signs and symptoms. Most AEs (95.5%) occurred 274 within 48 hours of vaccination. These results are consistent with those of several 275 previous studies, suggesting that local and systemic reactions are common[32,33], and 276 277 that all reported AEs were nonserious. Furthermore, our study showed results related to neurological aspects after seasonal influenza vaccination in the hypertensive 278 population. Paraesthesias and dysesthesias (4.09%) were the main manifestations of 279 TIA, and nervous system disorders were found in 9.63% with QIA; the most frequent 280 AEs were headache NEC (3.33%), neurological signs and symptoms NEC (2.55%), 281 paresthesia, and dysesthesia (2.73%). In addition, no association was found between 282

283	FLUX and neurological aspects. Some studies have shown an association between the
284	incidence of Greene-Barrow syndrome[33], Acute Disseminated Encephalomyelitis
285	(ADEM), and seasonal influenza vaccination[34].
286	After TIA vaccination, there were 20 cases (0.88%) of disturbances in initiating
287	and maintaining sleep, and 37 cases (1.63%) of NEC skin injuries in the population.
288	Disturbances in initiating and maintaining sleep are psychiatric disorders; however, no
289	studies have been conducted on seasonal influenza vaccines and psychiatric disorders.
290	In a study evaluating the relationship between maternally inactivated influenza
291	vaccination (IIV) and the risk of diagnosis of neurodevelopmental disorders in early
292	childhood, no increased risk of neurodevelopmental disorders was found in children
293	after maternal exposure to IIV[35]. The majority of rare AEs associated with QIA,
294	including ear and labyrinth disorders (0.83%), eye disorders (1.03%), appetite disorders
295	(0.51%), and respiratory, thoracic, and mediastinal disorders (0.83%), may hinder
296	recovery in the hypertensive population. Rare AEs associated with vaccination with
297	FLUX were primarily NEC (4.88%) in the hypertensive population.
298	Clinical trials are the gold standard to evaluate the safety and efficacy of new
299	vaccines. However, they have limitations in evaluating rare AEs due to the short
300	observation period and limited size of the testing populations. Post-marketing
301	surveillance, such as a spontaneous reporting database, plays a critical role in
302	continually monitoring the safety signals of AEs[36]. Nevertheless, our study had some
303	limitations. First, the VAERS database suffers from underreporting, overreporting,

304	missing data, and possible reporting based on indirect information such as media
305	sources[32]. Thus, mild-to-moderate or severe AEs may be rarer than our findings[31].
306	Moreover, we cannot rule out the possibility of conditions or regulatory agency
307	interventions due to unadjusted confounders, such as exposure to previous infections
308	and individual occupational characteristics[37,38], which may affect the VAERS
309	database information based on the year of reporting. Therefore, our findings may have
310	involved unknown or invalidated AEs. Furthermore, the reduced sample size of the
311	post-PSM study may have led to a selection bias, and we used a limited number of
312	covariates that met the user-defined sample thresholds in the propensity score-matched
313	target outcome.

314

315 **Conclusion**

316 Our study provides insights into the AEs associated with seasonal influenza vaccination

in hypertensive individuals, highlighting common local and systemic reactions.

318 However, further research with larger and more diverse populations is needed to

319 confirm these findings and better understand the impact of specific AEs on recovery in

- 320 hypertensive populations. Additionally, ongoing post-marketing surveillance is
- 321 essential to continuously monitor the safety signals of AEs and to inform future

322 vaccination strategies.

323

324 Supporting information

325 S1 Appendix.

326 (DOCX)

327 Acknowledgments

328 The authors thank the study participants involved in this study.

329

330 Author contributions

- 331 Conceptualization: Hao Wu, Xiaona He
- 332 Data curation: Hao Wu
- 333 Formal analysis: Hao Wu, Yu Cao
- 334 Methodology: Hao Wu
- 335 Funding acquisition: Wei Gao
- 336 **Supervision:** Wei Gao
- 337 **Project administration:** Wei Gao
- 338 Writing-original draft: Hao Wu
- 339 Writing-review & editing: Wei Gao

340

341 **References**

- 342 [1] World Health Organization. Influenza (Seasonal). https://www.who.int/news-room/
- fact-sheets/detail/influenza-(seasonal) (accessed 29 August 2024).
- 344 [2] Hutchinson EC. Influenza Virus. Trends Microbiol. 2018;26:809–10.
- 345 https://doi.org/10.1016/J.TIM.2018.05.013.

- 346 [3] Martini M, Gazzaniga V, Bragazzi NL, Barberis I. The Spanish Influenza
- Pandemic: a lesson from history 100 years after 1918. J Prev Med Hyg. 2019;60:E64–
- 348 7. https://doi.org/10.15167/2421-4248/JPMH2019.60.1.1205.
- 349 [4] Akin L, Gözel MG. Understanding dynamics of pandemics. Turk J Med Sci.
- 350 2020;50:515–9. https://doi.org/10.3906/SAG-2004-133.
- 351 [5] Li J, Zhang Y, Zhang X, Liu L. Influenza and Universal Vaccine Research in China.
- 352 Viruses. 2022;15. https://doi.org/10.3390/V15010116.
- 353 [6] Czaja CA, Miller L, Alden N, Wald HL, Cummings CN, Rolfes MA, et al.
- 354 Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes
- 355 Among Older Adults Hospitalized With Influenza-U.S. Influenza Hospitalization
- 356 Surveillance Network (FluSurv-NET). Open Forum Infect Dis. 2019;6.
- 357 https://doi.org/10.1093/OFID/OFZ225.
- 358 [7] Holstein R, Dawood FS, O'Halloran A, Cummings C, Ujamaa D, Kirley PD, et al.
- 359 Characteristics and Outcomes of Hospitalized Pregnant Women With Influenza, 2010
- to 2019: A Repeated Cross-Sectional Study. Ann Intern Med. 2022;175:149-58.
- 361 https://doi.org/10.7326/M21-3668.
- 362 [8] Olson SM, Newhams MM, Halasa NB, Feldstein LR, Novak T, Weiss SL, et al.
- 363 Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children.
- Clinical Infectious Diseases. 2022;75:230–8. https://doi.org/10.1093/CID/CI AB931.
- 365 [9] Andrejko KL, Myers JF, Openshaw J, Fukui N, Li S, Watt JP, et al. Receipt of
- 366 COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022

367 influenza season. Vaccine. 2023;41:1190–7. https://doi.org/10.1016/J.VACCINE.
368 2022.12.052.

- 369 [10] Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine.
- 370 Vaccines (Basel). 2018;6. https://doi.org/10.3390/VACCINES6020019.
- [11] McKeage K. Inactivated quadrivalent split-virus seasonal influenza vaccine
 (Fluarix® Quadrivalent): A review of its use in the prevention of disease caused by
 influenza A and B. Drugs. 2013;73:1587–94. https://doi.org/10.1007/
 s40265-013-0114-3.
- 375 [12] Fens T, De Boer PT, Van Puijenbroek EP, Postma MJ. Inclusion of Safety-Related

376 Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic

- 377 Review. Vaccines (Basel). 2021;9:1–28. https://doi.org/10.3390/ VACCINES9020111.
- [13] Asturias EJ, Wharton M, Pless R, MacDonald NE, Chen RT, Andrews N, et al. 378 379 Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee Vaccine Safety 15 Vaccine. 2016;34:3342-9. 380 on at years. https://doi.org/10.1016/J.VACCINE.2016.05.018. 381
- [14] Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the
 Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398–405.
 https://doi.org/10.1016/J.VACCINE.2015.07.035.
- [15] Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al.
 Understanding vaccine safety information from the Vaccine Adverse Event Reporting
 System. Pediatr Infect Dis J. 2004;23:287–94. https://doi.org/10.1097/

388 00006454-200404000-00002.

- [16] World Health Organization. Causality assessment of an adverse event following
 immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019
 update. https://www.who.int/publications/i/item/9789241516990 (accessed 29 August
 2024).
- 393 [17] World Health Organizatio. Global manual on surveillance of adverse events
- 394 following immunization. https://www.who.int/publications/i/item/9789241507769
- 395 (accessed 29 August 2024).
- 396 [18] Newall AT, Chaiyakunapruk N, Lambach P, Hutubessy RCW. WHO guide on the
- 397 economic evaluation of influenza vaccination. Influenza Other Respir Viruses.
- 398 2018;12:211–9. https://doi.org/10.1111/IRV.12510.
- 399 [19] Chen Q, Wang L, Xie M, Li X. Recommendations for influenza and Streptococcus
- 400 pneumoniae vaccination in elderly people in China. Aging Med (Milton). 2020;3:1–11.
- 401 https://doi.org/10.1002/AGM2.12102.
- [20] Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for
 preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;2015.
 https://doi.org/10.1002/14651858.CD005050.PUB3.
- [21] Recommended adult immunization schedule for ages 19 years or older: United
 States, 2022. JAAPA. 2022;35:1–22. https://doi.org/10.1097/01.JAA.00008
 22520.39079.BD.
- 408 [22] Feng L, Peng Z, Wang D, Yang P, Yang J, Zhang Y, et al. Technical guidelines for

409 seasonal influenza vaccination in China, 2018-2019. Zhonghua Liu Xing Bing Xue Za

- 410 Zhi. 2018;39:1413–25. https://doi.org/10.3760/CMA.J.ISSN. 0254-6450.2018.11.001.
- 411 [23] Centers for Disease Control and Prevention. National Center for Immunization and
- 412 Respiratory Diseases (NCIRD). https://www.cdc.gov/about/leadership/leaders/ncird.
- 413 html (accessed 29 August 2024).
- 414 [24] Li Q, Zhang M, Chen H, Wu F, Xian J, Zheng L, et al. Influenza Vaccination
- 415 Coverage among Older Adults with Hypertension in Shenzhen, China: A
- 416 Cross-Sectional Survey during the COVID-19 Pandemic. Vaccines (Basel). 2021;9.
- 417 https://doi.org/10.3390/VACCINES9101105.
- 418 [25] Wang Q, Yue N, Zheng M, Wang D, Duan C, Yu X, et al. Influenza vaccination

419 coverage of population and the factors influencing influenza vaccination in mainland

- 420 China: A meta-analysis. Vaccine. 2018;36:7262–9.
 421 https://doi.org/10.1016/J.VACCINE. 2018.10.045.
- 422 [26] Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Safety: A
- 423 Summary for Clinicians. https://www.cdc.gov/flu/professionals/vaccination/vaccine_
- 424 safety.htm (accessed 29 August 2024).
- 425 [27] S. MS, V. SM, M. TN, M. Š-ZM. Medical dictionary MedDRA: Used in over 60
- 426 countries, among which is Montenegro. Hospital Pharmacology. 2015;2:266–71.
 427 https://doi.org/10.5937/HPIMJ1502266M.
- 428 [28] MedDRA. What's New with MedDRA Version 26.1.
 429 https://admin.meddra.org/sites/default/files/guidance/file/whatsnew_26_1_English.pdf

430 (accessed 29 August 2024).

- [29] Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities
 (MedDRA). Drug Saf. 1999;20:109–17. https://doi.org/10.2165/00002018-199920020-
- 433 00002.
- 434 [30] So CS, Jin SH, Kang WS. Propensity-Score-Matched Evaluation of Adverse
 435 Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA
- 436 Vaccines. Vaccines (Basel). 2022;10. https://doi.org/10.3390/VACC INES10020284.
- 437 [31] Ali MS, Prieto-Alhambra D, Lopes LC, Ramos D, Bispo N, Ichihara MY, et al.
- 438 Propensity score methods in health technology assessment: Principles, extended
 439 applications, and recent advances. Front Pharmacol. 2019;10. https://doi.org/10.3389/
- 440 FPHAR.2019.00973/PDF.
- 441 [32] Tebaa A, Benkirane R, Alj L, Cherkaoui I, Soulaymani-Bencheikh R. Monitoring
- the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco. Ther Adv
- 443 Vaccines Immunother. 2022;10. https://doi.org/10.1177/251513 55221088157.
- 444 [33] Gattás VL, Braga PE, Koike ME, Lucchesi MBB, de Oliveira MMM, Piorelli R de
- 445 O, et al. Safety assessment of seasonal trivalent influenza vaccine produced by Instituto
- 446 Butantan from 2013 to 2017. Rev Inst Med Trop Sao Paulo. 2018;61.
- 447 https://doi.org/10.1590/S1678-9946201961004.
- 448 [34] Fujimori M, Nakamura M. Association between seasonal influenza vaccines and
- the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine
- 450 Adverse Event Reporting System. Pharmazie. 2022;77:262-9.

451 https://doi.org/10.1691/PH.2022.2354.

- 452 [35] Foo D, Sarna M, Pereira G, Moore HC, Regan AK. Association between maternal
- 453 influenza vaccination and neurodevelopmental disorders in childhood: a longitudinal,
- 454 population-based linked cohort study. Arch Dis Child. 2023;108:647-53.
- 455 https://doi.org/10.1136/ARCHDISCHILD-2022-324269.
- 456 [36] Du J, Xiang Y, Sankaranarayanapillai M, Zhang M, Wang J, Si Y, et al. Extracting
- 457 postmarketing adverse events from safety reports in the vaccine adverse event reporting
- 458 system (VAERS) using deep learning. Journal of the American Medical Informatics
- 459 Association. 2021;28:1393–400. https://doi.org/10.1093/JAMIA/OCAB014.
- 460 [37] Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al.
- 461 Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. New
- 462 England Journal of Medicine 2021;385:1355-71. https://doi.org/10.1056/
- 463 NEJMOA2110362/SUPPL_FILE/NEJMOA2110362_DATA-SHARING.PDF.
- 464 [38] Mosterín Höpping A, McElhaney J, Fonville JM, Powers DC, Beyer WEP, Smith
- 465 DJ. The confounded effects of age and exposure history in response to influenza
- 466 vaccination. Vaccine. 2016;34:540–6.https://doi.org/10.1016/J.VACCINE.2015.11.058.

TIA







Therapeutic and nontherapeutic responses Disturbances in initiating and maintaining sleep Joint related signs and symptoms Musculoskeletal and connective tissue pain and discomfort Musculoskeletal and connective tissue conditions NEC Paraesthesias and dysaesthesias Disability issues Skin injuries NEC Injection site reactions Pain and discomfort NEC Dermal and epidermal conditions NEC Imaging procedures NEC

Hazard Ratio(HR)

N	HR	95%CI	P-value
19	5.85	2.92-11.74	<0.001
12	5.57	2.73-11.36	<0.001
17	5.35	2.74-10.43	<0.001
20	4.89	2.44-9.81	<0.001
20	4.53	2.29-8.95	<0.001
28	4.50	2.41-8.41	<0.001
12	4.06	1.85-8.89	<0.001
11	4.02	1.70-9.48	0.002
13	3.79	1.67-8.58	0.001
117	3.74	2.31-6.06	<0.001
378	3.69	2.35-5.78	<0.001
350	3.67	2.33-5.78	<0.001
17	3.63	1.78-7.41	<0.001
28	3.49	1.77-6.88	<0.001
10	3.39	1.50-7.68	0.003
150	3.33	2.08-5.34	<0.001
151	3.30	2.06-5.29	<0.001
12	3.20	1.20-8.52	0.020
18	3.18	1.40-7.21	0.006
67	3.13	1.84-5.33	<0.001
64	2.87	1.645-4.99	<0.001
39	2.84	1.57-5.12	<0.001
1105	2.81	1.81-4.37	<0.001
15	2.80	1.37-5.717	0.005
12	2.75	1.26-6.03	0.011
20	2.65	1.32-5.32	0.006
29	2.60	1.30-5.21	0.007
17	2.58	1.14-5.84	0.023
139	2.58	1.56-4.25	<0.001
28	2.57	1.30-5.07	0.007

38 2.51 1.43-4.40 0.001

Multivariate analysis

QIA Skin injuries NEC Bursal disorders Hearing losses medRxiv preprint doi: https://doi.org/10.1101/2024.09.03.24313030; this version posted September 4,12024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International lice Inflammations Disturbances in initiating and maintaining sleep Ear disorders NEC Bone related signs and symptoms Oedema NEC Musculoskeletal and connective tissue conditions NEC Musculoskeletal and connective tissue pain and discomfort Pain and discomfort NEC Sleep disorders NEC Ocular infections, inflammations and associated manifestations Vaccination related complications Joint related signs and symptoms Paraesthesias and dysaesthesias Anxiety symptoms Carbohydrate tolerance analyses (incl diabetes) Muscle pains Therapeutic and nontherapeutic responses Disability issues Injection site reactions Protein analyses NEC Musculoskeletal and soft tissue imaging procedures Therapeutic procedures NEC Ocular disorders NEC Inner ear signs and symptoms Pruritus NEC Appetite disorders Muscle weakness conditions

0

Hazard Ratio(HR)

4

8

12

Fig 2.

FLUX



Fig 3.